Drugs / HS-196
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03333031 | Aug 2018 → Oct 2020 | cancer | Herbert Lyerly | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-196 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03333031 ↗ |
| Action | Inhibit | “HS-196 consists of a HSP90 inhibitor that binds competitively to the Hsp90 ATP binding domain” NCT03333031 ↗ |
| Modality | Diagnostic / imaging agent | “HS-196 is a tumor imaging agent.” NCT03333031 ↗ |
| Route | Intravenous | “HS-196 will be administered intravenously as a single dose” NCT03333031 ↗ |